Nektar’s Immunotherapy Paired with BMS’ Blockbuster Opdivo Missed Key Endpoints in Melanoma Trial

Nektar Therapeutics’ experimental immunotherapy bempegaldesleukin paired with Bristol Myers Squibb’s (BMS) blockbuster checkpoint inhibitor, Opdivo (nivolumab), did not shrink tumors, slow the growth of tumors or prolong survival rates for…

Continue ReadingNektar’s Immunotherapy Paired with BMS’ Blockbuster Opdivo Missed Key Endpoints in Melanoma Trial